Serologic antiglycan antibodies in inflammatory bowel disease

American Journal of Gastroenterology

Volumn 106, Issue 3, 2011, Pages 406-412

  Lakatos, Peter Laszlo ^a   Papp, Maria ^b   Rieder, Florian ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CHITIN CARBOHYDRATE IMMUNOGLOBULIN ANTIBODY; CHITOBIOSIDE CARBOHYDRATE IMMUNOGLOBULIN A ANTIBODY; FUNGUS ANTIBODY; IMMUNOGLOBULIN ANTIBODY; INFLIXIMAB; LAMINARIBIOSIDE CARBOHYDRATE IMMUNOGLOBULIN G ANTIBODY; LAMINARIN CARBOHYDRATE IMMUNOGLOBULIN ANTIBODY; MANNOBIOSIDE CARBOHYDRATE IMMUNOGLOBULIN G ANTIBODY; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; COLON FISTULA; COLON OBSTRUCTION; CROHN DISEASE; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; HIGH RISK PATIENT; HUMAN; NONHUMAN; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TREATMENT PLANNING; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTIBODIES; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; PHENOTYPE; POLYSACCHARIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 79952361823     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.505     Document Type: Review

References (58)

1. Stange EF, Travis SP, Vermeire S et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55 (Suppl 1):i1-15.
2. Stange EF, Travis SP, Vermeire S et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23. (Pubitemid 351179487)
3. Louis E, Collard A, Oger AF et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-82. (Pubitemid 33096034)
4. Targan SR, Landers CJ, Yang H et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005;128:2020-8. (Pubitemid 40824710)
5. Dotan I, Fishman S, Dgani Y et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006;131:366-78. (Pubitemid 44142445)
6. Mow WS, Vasiliauskas EA, Lin YC et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004;126:414-24. (Pubitemid 38182298)
7. Papp M, Norman GL, Altorjay I et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol 2007;13:2028-36. (Pubitemid 46795837)
8. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34. (Pubitemid 47123518)
9. Vermeire S, Joossens S, Peeters M et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827-33. (Pubitemid 32193179)
10. Targan SR. The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm Bowel Dis 1999;5:61-3.
11. Dubinsky MC, Ofman JJ, Urman M et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001;96:758-65. (Pubitemid 32240727)
12. Koutroubakis IE, Petinaki E, Mouzas IA et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:449-54.
13. Dubinsky MC, Kugathasan S, Mei L et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008;10:1105-11.
14. Papp M, Altorjay I, Dotan N et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008;103:665-81. (Pubitemid 351405992)
15. Henckaerts L, Pierik M, Joossens M et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007;56:1536-42. (Pubitemid 350033192)
16. Dassopoulos T, Frangakis C, Cruz-Correa M et al. Antibodies to saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis 2007;13:143-51. (Pubitemid 46806222)
17. Lakatos PL, Altorjay I, Mandi Y et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins? Tissue Antigens 2008;71:552-9. (Pubitemid 351697252)
18. Rieder F, Schleder S, Wolf A et al. Association of the novel serologic antiglycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis 2010;16:263-74.
19. Desir B, Amre DK, Lu SE et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004;2:139-46. (Pubitemid 38180468)
20. Ruemmele FM, Targan SR, Levy G et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9. (Pubitemid 28452928)
21. Granito A, Muratori L, Muratori P et al. Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. Gut 2006;55:296. (Pubitemid 43117295)
22. Reddy KR, Colombel JF, Poulain D et al. Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. Am J Gastroenterol 2001;96 : 252-3. (Pubitemid 32104843)
23. Papp M, Vitalis Z, Tornai I et al. Presence of anti-microbial antibodies is associated with increased risk for systemic infections in a large Hungarian cohort of patients with liver cirrhosis. GUT 2009;58 (Suppl II):1254.
24. Krause I, Monselise Y, Milo G et al. Anti-Saccharomyces cerevisiae antibodies - a novel serologic marker for Behcet's disease. Clin Exp Rheumatol 2002;20:S21-4.
25. Monselise A, Weinberger A, Monselise Y et al. Anti-Saccharomyces cerevisiae antibodies in Behcet's disease-a familial study. Clin Exp Rheumatol 2006;24:S87-90. (Pubitemid 44696885)
26. Dai H, Li Z, Zhang Y et al. Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus. Lupus 2009;18:1087-90.
27. Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum 2000;43:1487-96.
28. Sandborn WJ, Loft us ## Jr EV, Colombel JF et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001;7:192-201. (Pubitemid 32776511)
29. Joossens S, Reinisch W, Vermeire S et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-7. (Pubitemid 34465166)
30. Peeters M, Joossens S, Vermeire S et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730-4. (Pubitemid 32240723)
31. Ferrante M, Henckaerts L, Joossens M et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour . Gut 2007;56:1394-403. (Pubitemid 47517833)
32. Reumaux D, Sendid B, Poulain D et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003;17:19-35.
33. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50. (Pubitemid 34784976)
34. Veloso FT, Ferreira JT, Barros L et al. Clinical outcome of Crohn's disease: analysis according to the Vienna Classification and clinical activity. Inflamm Bowel Dis 2001;7:306-13.
35. Odes S, Vardi H, Friger M et al. Effect of phenotype on health care costs in Crohn's disease: a European study using the Montreal classification. J Crohns Colitis 2007;1:87-96. (Pubitemid 350278497)
36. Loly C, Belaiche J, Louis E. Predictors of severe Crohn' s disease. Scand J Gastroenterol 2008;43:948-54.
37. Gupta N, Cohen SA, Bostrom AG et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 2006;130 : 1069-77.
38. Seow CH, Stempak JM, Xu W et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 2009;104:1426-34.
39. Simondi D, Mengozzi G, Betteto S et al. Antiglycan antibodies as serological markers in the Differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:645-51. (Pubitemid 351742981)
40. Vasiliauskas EA, Kam LY, Karp LC et al. Marker antibody expression strati- fies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
41. Forcione DG, Rosen MJ, Kisiel JB et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004;53:1117-22. (Pubitemid 38961964)
42. Arnott ID, Landers CJ, Nimmo EJ et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004;99:2376-84. (Pubitemid 40039369)
43. Amre DK, Lu SE, Costea F et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006;101:645-52. (Pubitemid 43340944)
44. Rieder F, Schleder S, Wolf A et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010;8:1367-75.
45. Israeli E, Grotto I, Gilburd B et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6. (Pubitemid 41192480)
46. Markowitz J, Kugathasan S, Dubinsky M et al. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis 2009;15:714-9.
47. Quinton JF, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91. (Pubitemid 28277217)
48. Bartunkova J, Kolarova I, Sediva A et al. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin Immunol 2002;102:162-8. (Pubitemid 34171515)
49. Teml A, Kratzer V, Schneider B et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003;98:2226-31. (Pubitemid 37305363)
50. Esters N, Vermeire S, Joossens S et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002;97:1458-62. (Pubitemid 34664792)
51. Joossens M, Van Steen K, Branche J et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflamm Bowel Dis 2010;16:58-67.
52. Ashorn S, Raukola H, Valineva T et al. Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease. J Clin Immunol 2008;28:486-94.
53. Mallant-Hent R, Mary B, von Blomberg E et al. Disappearance of anti-Saccharomyces cerevisiae antibodies in coeliac disease during a gluten-free diet. Eur J Gastroenterol Hepatol 2006;18:75-8. (Pubitemid 43004885)
54. Papp M, Foldi I, Altorjay I et al. Anti-microbial antibodies in celiac disease: trick or treat? World J Gastroenterol 2009;15:3891-900.
55. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-33. (Pubitemid 40289486)
56. Landers CJ, Cohavy O, Misra R et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002;123:689-99. (Pubitemid 34977074)
57. Vandewalle-El Khoury P, Colombel JF, Joossens S et al. Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to Differential diagnosis, stratification, and prediction. Am J Gastroenterol 2008;103 : 949-57. (Pubitemid 351501080)
58. Lakatos PL, Altorjay I, Szamosi T et al. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis 2009;15:365-74.